Integrative reverse vaccinology and computational modeling for the rational design of a broadly immunogenic multi-epitope vaccine against Marburg virus infection.

Structure-Guided Immunoinformatics for the Rational Design of a Multi-Epitope Vaccine Against Batai Orthobunyavirus

This study presents a structurally optimized and validated multiepitope vaccine candidate against the emerging Batai orthobunyavirus, identifying a promising vaccine candidate for further investigation; however, its immunogenicity, safety, and protective efficacy before further vaccine development can be considered.

Harnessing reverse vaccinology for the design and validation of mRNA vaccine targeting the glycoprotein of human metapneumovirus (HMPV)

The two proposed multi-epitope mRNA vaccine constructs showed promising immunogenic, safety, and structural properties in silico, highlighting their potential as candidate vaccines against HMPV.

Design of a Novel Multi-Epitope mRNA Vaccine against Marburg Virus using Reverse Vaccinology

Aim: The Marburg virus (MARV), a zoonotic pathogen, causes a severe hemorrhagic fever for which no approved vaccine currently exists. Methods: This study used reverse vaccinology to develop a multi-epitope vaccine against Marburg virus (MARV). To improve stability and translational efficiency, the construct was modified as an mRNA vaccine by adding a 5′ cap, 5′ UTR, Kozak sequence, tPA signal peptide, 3′ UTR, and poly(A) tail. Results: We selected the potential 06 CTL, 06 HTL, and 04 LBL epitopes with high antigenicity, no allergenicity, and no toxicity, and the epitopes were linked with the linkers (GPGPG, AAY, KK) and an adjuvant (β-defensin 2). The designed vaccine showed an antigenic score of 0.7189 with promising properties. Molecular docking reveals that the vaccine exhibits a strong binding affinity with human TLR4 (-1301.5 kcal/mol). Meanwhile, MD simulation confirms its structural stability, and immune simulations indicate robust cellular and humoral immune responses. Ultimately, in silico cloning validated the capacity for effective expression in E. coli. Finally, secondary structure revealed that the mRNA vaccine (-418.59 kcal/mol) was thermodynamically stable. These outcomes may contribute to the development of an experimental MARV vaccine. Conclusions: However, further experimental evaluation is necessary to assess the efficacy of the modified mRNA vaccine for MARV prevention.

Integrative immunoinformatics and structural modeling for the rational design of a multi-epitope vaccine candidate against human cytomegalovirus

The results highlight the potential of the proposed multi-epitope construct as a promising vaccine candidate against HCMV, however, experimental validation is essential to confirm its immunogenicity, safety, and translational applicability.

In Silico design and evaluation of a multi-epitope vaccine candidate against Toxoplasma gondii for humans

The rationally designed multi-epitope vaccine demonstrates robust theoretical potential to elicit comprehensive, long-lasting immunity in humans, although its safety and effectiveness require additional experimental validation.

Immunoinformatics-guided design of a conserved multi-epitope vaccine candidate against pathogenic human coronaviruses.